Arterial Network was informed July 24, the world's leading medical device manufacturers Holter Peng Yang announced the completion of a new round of medical tens of million A round of financing. The investor in this round is the Jianyin Medical Growth Fund, and the Qingke Project Workshop is the exclusive financial advisor. This round of financing will be used for marketing network layout, series product development and approval, academic promotion and brand building, product and technology acquisition. Pengyang Medical is a medical device manufacturer specializing in cardiovascular disease testing. Its product matrix includes 18-lead/12-lead Holter, dynamic blood pressure, dynamic ECG network, and multi-parameter Holter. Its core innovative product is the "18-lead full information dynamic ECG analysis system", which is 18 guide Holter products: MedSun-V18. Not only in China, but also the world's leading exclusive products. At present, the number of cardiovascular patients in China has reached 290 million, and cardiovascular deaths account for more than 40% of deaths in residents, which is much higher than the mortality rate of cancer and other diseases. The growing burden of cardiovascular disease has become a major public health problem. At present, there are widespread pain points in the field of domestic dynamic electrocardiogram: One, 12 guide Holter can not detect the myoelectric signal of the left ventricle posterior wall and right ventricle of the heart, which is easy to cause misdiagnosis of missed diagnosis, which is not conducive to the establishment of a large ECG database. Second, the patient is inconvenient to wear, the hardware acquisition anti-interference ability is poor, the acquisition is not accurate, and the automatic diagnosis result is too vague. Third, the software analysis system is too cumbersome, the doctor's interpretation time is too long, affecting work efficiency. Based on the above pain points, Pengyang Medical has cooperated with many well-known hospitals, universities and scientific research institutions in China through many years of research and development, and has produced exclusive global innovative products with exclusive independent intellectual property rights, which has completely solved the traditional dynamic heart for many years. In the field of electrical diagnosis, the problem of comprehensive omnidirectional and full information coverage cannot be carried out. Its fully intelligent pre-analysis system can also automatically diagnose the conclusions at a rapid speed, save doctors more than 50% of the interpretation time, greatly improve work efficiency, provide a more comprehensive and accurate scientific basis for accurate diagnosis and treatment of clinical medicine, and also provide patients with a scientific basis. More convenient and more comfortable to wear. The China ECEC has jointly established the “Pengyang Fund†with Pengyang Medical to jointly promote the development of China's electrocardiogram and popularize the application of 18-channel Holter products. At present, academic promotion conferences have been held in Beijing, Shandong, Henan, Fujian, Hebei and other places. The series of products have been highly recognized and praised by many ECG experts and local electrocardiographers. Regarding this round of financing, Han Jing, a partner of the project workshop and partner of Zero2IPO Capital, said: “The project workshop is honored to assist in the completion of this financing. In the context of low-cost competition among domestic enterprises, it is very fortunate to be able to see a revolutionary Technological innovation companies stand out, their main products and technologies are in the forefront of the world, and have been striving for the improvement of China's medical technology and the improvement of the level of diagnosis and treatment. The project workshop is committed to providing "online + offline" for entrepreneurs. Full-scale financing services, to the greatest extent, the integration of resources by the enterprise to help its sustainable development. About Jianyin Medical Growth Fund The CCB Medical Growth Fund is a private equity fund that is invested in the marketization of CCB International and focuses on investment in middle- and early-stage, growth-oriented quality healthcare companies. The fund relies on the Kunshan High-tech Zone to give full play to the advantages of the joint investment of CCB International Investment Bank and the professional investment team of the medical and health industry. Combining the future high-quality medical and health industry resources of the People's Republic of China, the Bank accurately selects the scientific and technological industrialization projects in the medical and health industry and accelerates the cultivation of the medical and health industry. Innovative technology companies in the field focus on providing comprehensive post-investment value-added services for investment companies, and are committed to growing together with companies and shareholders to realize value. Edible Starch 9 Letters,Alcohol Edible Corn Starch,Edible Starch Crossword Clue,Raw Eating Cornstarches JILIN COFCO BIO-CHEM AND BIO-ENERGY MARKETING CO., LTD , https://www.cofco-biotech.com
